SSc/Myositis | SSc/RA | SSc/SS | SSc/SLE | |||||
---|---|---|---|---|---|---|---|---|
lcSSC, n (%) | dcSSc, n (%) | lcSSC, n (%) | dcSSc, n (%) | lcSSC, n (%) | dcSSc, n (%) | lcSSC, n (%) | dcSSc, n (%) | |
Patients | 73 (57.5) | 51 (40.2) | 80 (84.2) | 15 (15.8) | 41 (82) | 9 (18) | 19 (76) | 6 (24) |
ANA | 73 (100) | 50 (98) | 76 (95) | 14 (93.3) | 39 (95.1) | 9 (100) | 19 (100) | 6 (100) |
ACA | — | — | 23 (28.8) | — | 21 (51.2) | — | 2 (10.5) | — |
Scl-70 | 4 (5.5) | 6 (11.7) | 13 (16.3) | 4 (26.7) | 3 (7.3) | 5 (55.6) | 3 (15.8) | — |
U1RNP | 14 (19.2) | 6 (11.7) | 9 (11.3) | — | 6 (14.6) | — | 8 (42.1) | 3 (50) |
Ro | 5 (6.8) | 3 (5.9) | 7 (8.8) | 4 (26.7) | 13 (31.7) | 1 (11.1) | 2 (10) | 1 (16.7) |
La | 1 (1.4) | 1 (2) | 4 (5) | — | 5 (12.2) | — | — | — |
PM/Scl | 25 (34.2) | 17 (33.3) | 7 (8.8) | 2 (13.3) | — | 1 (11.1) | — | — |
Jo-1 | 7 (9.6) | 1 (2) | — | 1 (6.7) | — | — | — | — |
RNAP | 1 (1.4) | 3 (5.9) | 3 (3.8) | 1 (6.7) | — | 1 (11.1) | — | — |
U3RNP | 2 (2.8) | 6 (11.7) | 1 (1.3) | — | — | — | — | 1 (16.7) |
SSc: systemic sclerosis; RA: rheumatoid arthritis; SS: Sjögren’s syndrome; SLE: systemic lupus erythematosus; lcSSc: limited cutaneous systemic sclerosis; dcSSc: diffuse cutaneous systemic sclerosis; ANA: antinuclear antibody; ACA: anticentromere antibody; Scl-70: antitopoisomerase I Antibody; RNAP: RNA polymerase antibody.